Healios KK (JP:4593) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healios K.K. has announced its decision to apply for conditional and time-limited approval in Japan for its MultiStem® therapy for acute respiratory distress syndrome (ARDS), based on positive Phase 2 trial results. The company plans to launch a global Phase 3 trial in the U.S. and has cancelled a previously planned Phase 3 trial in Japan. Healios has stated that this development will not affect its consolidated financial results for the fiscal year ending December 31, 2024.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.